Back
to sessions
Sep 27
Scientific
MODERATOR(S)
Harriet Eldredge-Hindy, MD - Medical University of South Carolina
Amitabh Ray, MD, MBBS, DNB - Chittaranjan National Cancer Institute
Credits
| AMA PRA Category 1 Credits: | 1.00 |
| CAMPEP Credits: | 1.00 |
| MDCB Credits: | 1.00 |
Presentations
-
05:00pm - 05:10pm ET
Long-Term Outcomes from a Phase 2 Trial of Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma
Speaker: Xingzhe Li, MD, MPH - UT Southwestern Medical Center, Dallas -
05:10pm - 05:20pm ET
Efficacy and Safety of Targeted-Immunotherapy with or without Stereotactic Ablative Radiotherapy for Recurrent/Metastatic Renal Cell Carcinoma: The Result of a Multicenter Ambidirectional cohort study
Speaker: Ke Hu, MD - Peking University First Hospital, Beijing -
05:20pm - 05:30pm ET
Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) for Localized Renal Pelvic and Ureteral Carcinoma
Speaker: Xiaoying Li, MD - Peking University First Hospital, Beijing -
05:30pm - 05:40pm ET
Evaluation of 68Ga-NYM 096 CAIX PET/CT for Systemic Therapy-Radiotherapy Integration and Target Definition in Metastatic ccRCC (NYCRRT)
Speaker: Mingwei Ma, MD - Peking University First Hospital, Beijing -
05:40pm - 05:50pm ET
Locoregional Recurrence in pT3-4/pN+ Muscle-Invasive Bladder Cancer Receiving Modern Perioperative Systemic Therapy: A Propensity Score-Matched Competing Risk Analysis
Speaker: Tian Cheng, MD, MBBS - Peking University First Hospital, Beijing -
05:50pm - 06:00pm ET
Adaptive Radioresistance in Muscle-Invasive Bladder Cancer Is Driven by Tumour-Microenvironment Co-Evolution and Enables Biomarker-Guided Radiotherapy
Speaker: Ananya Choudhury, PhD, MA MRCP FRCR - The Christie NHS Foundation Trust and University of Manchester, Manchester